Leukemia Research
Volume 34, Issue 10 , Pages 1330-1335 , October 2010

The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group

  • Anna Dmoszynska

      Affiliations

    • Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
    • Corresponding Author InformationCorresponding author. Tel.: +48 81 53 45 468; fax: +48 81 53 45 605.
    • ,
  • Adam Walter-Croneck

      Affiliations

    • Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
    • ,
  • Iwona Hus

      Affiliations

    • Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
    • ,
  • Norbert Grzasko

      Affiliations

    • Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
    • ,
  • Joanna Manko

      Affiliations

    • Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
    • ,
  • Wieslaw Wiktor Jedrzejczak

      Affiliations

    • Department of Haematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland
    • ,
  • Grzegorz Charlinski

      Affiliations

    • Department of Haematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland
    • ,
  • Lidia Usnarska-Zubkiewicz

      Affiliations

    • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland
    • ,
  • Aleksander Skotnicki

      Affiliations

    • Department of Haematology, Collegium Medicum, Jagiellonian University, Krakow, Poland
    • ,
  • Teresa Wolska-Smolen

      Affiliations

    • Department of Haematology, Collegium Medicum, Jagiellonian University, Krakow, Poland
    • ,
  • Jaroslaw Piszcz

      Affiliations

    • Department of Haematology, Medical University of Bialystok, Poland
    • ,
  • Janusz Kloczko

      Affiliations

    • Department of Haematology, Medical University of Bialystok, Poland

Received 25 November 2009 ,Revised 26 March 2010 ,Accepted 7 May 2010.

References 

  1. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571
  2. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000;109:89–96
  3. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica. 2001;86:404–408
  4. Leleu X, Magro L, Fawaz A, Bauters F, Facon T, Yakoub-Agha I. Efficacy of a low dose of thalidomide in advanced multiple myeloma. Blood. 2002;100:1519–1520
  5. Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004;5:112–117
  6. Palumbo A, Bertola A, Falco P, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J. 2004;5:318–324
  7. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003;121:768–771
  8. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112:3107–3114
  9. Suvannasankha A, Fausel C, Juliar BE, et al. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21. Oncologist. 2007;12:99–106
  10. Kim YK, Lee JJ, Lee SR, et al. Clinical efficacy of thalidomide containing regimens as a first line therapy in patients with multiple myeloma. Haematologica. 2007;92(Suppl. 2):177;[abstr.]
  11. Wu P, Davies FE, Horton C, et al. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide–vincristine–doxorubicin–methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma. 2006;47:2335–2338
  12. Fiserova A, Hajek R, Holubova V, et al. Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells. Neoplasma. 2002;49:300–306
  13. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115–1123
  14. Alexanian R, Weber D, Anagnostopoulos A, et al. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol. 2003;40(4 Suppl. 4):3–7
  15. Roussou M, Anagnostopoulos A, Kastritis , et al. Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatments. Leuk Lymphoma. 2007;48:754–758
  16. Kyriakou C, Thomson K, D'Sa S, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol. 2005;129:763–770
  17. Hus I, Dmoszynska A, Manko J, et al. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. Br J Cancer. 2004;91:1873–1879
  18. Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol. 2003;122:607–616
  19. García-Sanz R, González-Porras JR, Hernández JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia. 2004;18:856–863
  20. Morgan G, Davies FE, Owen RG, et al. Thalidomide combination improve response rates; results from MRC IX study. Blood. 2007;110:1051A
  21. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80:1568–1574
  22. Palumbo A, Rus C, Zeldis JB, et al. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. Italian Multiple Myeloma Network, Gimema. J Thromb Haemost. 2006;4:1842–1845
  23. Mangles SE, Abdalla SH. CTD treatment of myeloma - a single institution's experience. Haematologica. 2007;92(Suppl. 2):169

PII: S0145-2126(10)00247-X

doi: 10.1016/j.leukres.2010.05.003

Leukemia Research
Volume 34, Issue 10 , Pages 1330-1335 , October 2010

Article Tools

* Image Usage & Resolution